共 38 条
- [35] CAN USE OF HIGH COST DRUGS FOR RARE RHEUMATIC DISEASES BE RELIABLY IDENTIFIED WITHIN ROUTINELY COLLECTED NHS DATA? RESULTS FROM A PILOT STUDY OF RITUXIMAB USE IN VASCULITIS USING DATA FROM THE NATIONAL DISEASE REGISTRATION SERVICE (NDRS) AND THE REGISTRATION OF COMPLEX RARE DISEASES - EXEMPLARS IN RHEUMATOLOGY (RECORDER) PROJECT RHEUMATOLOGY, 2021, 60
- [36] IDENTIFYING HIGH-COST DRUGS FOR RARE RHEUMATIC DISEASES IN ROUTINELY COLLECTED NHS DATA. RESULTS FROM A PILOT STUDY OF RITUXIMAB USE IN VASCULITIS USING DATA FROM THE NATIONAL DISEASE REGISTRATION SERVICE AND THE REGISTRATION OF COMPLEX RARE DISEASES-EXEMPLARS IN RHEUMATOLOGY (RECORDER) PROJECT ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 989 - 990
- [37] P091 Can use of high cost drugs for rare rheumatic diseases be reliably identified within routinely collected NHS data? Results from a pilot study of rituximab use in vasculitis using data from the National Disease Registration Service (NDRS) and the Registration of Complex Rare Diseases-Exemplars in Rheumatology (RECORDER) project RHEUMATOLOGY, 2021, 60